English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the early trials exploring the benefit of antihypertensive drug treatment, diastolic blood pressure (DBP) was chosen as the only criterion for patient inclusion. This choice had, by definition, influenced the baseline characteristics of the hypertensive population.1 The subjects with both high systolic blood pressure (SBP) and low DBP and, hence, with a selectively increased pulse pressure (PP) were excluded from the trials and, therefore, not analyzed in the primary results. This bias was introduced not only in selecting the subjects at inclusion, but also at the end of follow-up. Those with an elevated SBP were considered adequately treated, although only DBP had been normalized (≤90 mm Hg). Perhaps for these reasons, antihypertensive drug therapy was consistently shown to prevent stroke more than it prevented ischemic heart disease.1 Such findings suggested that more attention should be given to SBP2 and PP,3 both of which are better independent predictors of cardiovascular (CV) risk than DBP alone.In recent years, numerous therapeutic trials using SBP as the principal inclusion criterion were performed in elderly populations. Cardiac events were reduced by ≈24% to 27%, which is somewhat higher than that obtained in DBP-based trials.4 This diminution of cardiac events in SBP-based trials could reflect the choice of SBP as the specific enrolled criterion or the fact that these trials included only elderly subjects. Nevertheless, in the Hypertension Optimal Treatment (HOT) study,5 which was performed in middle-aged hypertensive subjects with systolic-diastolic hypertension, the failure to prove a benefit in terms of CV risk with a rigorously controlled DBP may be attributed to the fact that, although a decrease of SBP was indeed obtained, this decrease was less than that with DBP, and thus PP remained elevated.4 The concept that PP plays an independent role in CV risk …

Epidemiological Findings Imply That Goals for Drug Treatment of Hypertension Need to Be Revised